Compounds > irofulven
Page last updated: 2024-09-04

irofulven and Local Neoplasm Recurrence

irofulven has been researched along with Local Neoplasm Recurrence in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blessing, JA; McMeekin, S; Miller, DS; Muller, CY; Rotmensch, J; Schilder, RJ; Shahin, MS; Tewari, KS; Warshal, DP1
Blessing, JA; Pearl, ML; Rose, PG; Schilder, RJ1
Alberts, DS; Bodurka, DC; Cullen, M; Gordon, AN; Matulonis, UA; McGuire, WP; Penson, RT; Reed, E; Seiden, MV; Weems, G1
Beale, P; Boyer, M; Chan, AT; Chung, HC; Clarke, S; Goh, BC; Ho, R; Jeung, HC; Lam, KC; Lim, R; Ma, B; Mo, FK; Ng, EK; Ong, SY; Rha, SY; Roh, JK; Soo, R; Yeo, W; Zee, B1

Trials

4 trial(s) available for irofulven and Local Neoplasm Recurrence

ArticleYear
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Sesquiterpenes; Survival Rate; Treatment Outcome

2010
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
    Investigational new drugs, 2004, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Sesquiterpenes; Treatment Outcome; Vomiting

2004
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
    Gynecologic oncology, 2006, Volume: 101, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Sesquiterpenes

2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Infusions, Intravenous; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Sesquiterpenes; Stomach Neoplasms; Survival Rate; Treatment Outcome

2007